LAPTM4B polymorphism increases susceptibility to multiple cancers in Chinese populations: a meta-analysis by Cuiju Mo et al.
Mo et al. BMC Genetics 2014, 15:48
http://www.biomedcentral.com/1471-2156/15/48RESEARCH ARTICLE Open AccessLAPTM4B polymorphism increases susceptibility
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meta-analysis
Cuiju Mo, Yu Lu, Yan Deng, Jian Wang, Li Xie, Taijie Li, Yu He, Qiliu Peng, Xue Qin and Shan Li*Abstract
Background: Lysosome-associated protein transmembrane-4 beta (LAPTM4B) is a novel cancer-related gene. While
recent studies have reported that the LAPTM4B polymorphism increased the susceptibility of several cancers, the results
remain inconclusive. Therefore, we performed a meta-analysis to systematically summarize the possible association.
Results: The meta-analysis was conducted based on 17 studies in Chinese populations, including 4160 cases and 4148
controls. The relevant studies were searched through electronic databases updated in November 2013. The strength of
association between the LAPTM4B polymorphism and susceptibility to multiple cancers was assessed by odds ratio (OR)
and 95% confidence interval (95% CI).
The meta-analysis results suggested that the LAPTM4B polymorphism was significantly associated with overall
susceptibility to multiple cancers in all genetic models (*2 vs. *1, OR = 1.53, 95% CI = 1.37–1.70; *2/2 vs. *1/1,
OR = 2.18, 95% CI = 1.72–2.75; *2/1 vs.*1/1, OR = 1.62, 95% CI = 1.41–1.86; *2/1 + *2/2 vs. *1/1, OR = 1.70, 95%
CI = 1.47–1.97; *2/2 vs. *2/1 + *1/1, OR = 1.76, 95% CI = 1.50–2.05). Further subgroup analysis revealed a significant
association between the LAPTM4B polymorphism and cancer susceptibility in the subgroups stratified by control source,
cancer type, histopathologic differentiation, and TNM stage.
Conclusions: This meta-analysis indicated that the LAPTM4B *2 allele was associated with increasing risk of multiple
cancers, tumor initiation and development.
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Cancer is one of the leading causes of death in both devel-
oped and developing countries, genetic factors contribute
significantly to carcinogenesis [1]. Lysosome-associated
protein transmembrane-4 beta (LAPTM4B) is a novel
cancer-related gene that was cloned from hepatocellular
carcinoma (HCC) tissues using fluorescence differential
display, rapid amplification of cDNA ends (RACE), and
reverse transcription polymerase chain reaction (RT–
PCR) [2,3]. According to BLAST program analysis, the
LAPTM4B gene is composed of seven exons and six
introns mapped to chromosome 8q22 [4]. The full
length of messenger RNA for this gene is 2245 bp,
which encoded a lysosome-associated protein with four* Correspondence: lis8858@126.com
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unless otherwise stated.transmembrane regions. Because it is 46% homologous
with a human lysosome-associated transmembrane-4
protein (LAPTM4A) at the amino acid level, it was
named LAPTM4B by the International Committee [5].
In previous studies, LAPTM4B mRNA and protein were
found to be overexpressed in HCC tissues and expressed
at fairly low levels in noncancerous or normal liver tissues.
In addition, the expression levels were associated with
the differentiation status of HCC; it exhibited higher
expression in poor-differentiated HCC than in moderate
and well-differentiated HCC [4-6]. Recently, upregulated
LAPTM4B expression was also found in many other
malignant tumors, such as breast cancer [7], pancreatic
cancer [8], and gallbladder carcinoma (GBC) [9]. LAP
TM4B has important roles in many biological processes,
including malignant transformation; cell proliferation,
invasion, metastasis, and apoptosis; and signal trans-
duction [9,10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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accession number AY219176) and LAPTM4B *2 (Gen-
Bank accession number AY219177) [11]. The difference
between allele *1 and allele *2 is at the 5’UTR in the first
exon; allele *1 contains only a single 19-bp segment,
whereas allele *2 has two tandem repeats of the 19-bp
segment. LAPTM4B allele *1 produces a 317-amino acid
protein, while allele *2 was predicted to encode a 370-
amino acid protein; there are 53 extra amino acids at
the N-terminus of the proteins produced by allele *2 [4].
Recent studies have reported that the LAPTM4B poly-
morphism is associated with cancer risk. The LAPTM4B
*2 allele is reportedly associated with increased risk of
such cancers as liver, gastric, colon, and gallbladder cancer,
but not with rectal, oesophageal, or pancreatic carcinoma.
Given these controversial results and the limits of a single
study with a small sample size, we performed the present
meta-analysis of all eligible studies in Chinese populations
to investigate the association between the LAPTM4B
polymorphism and susceptibility to multiple cancers.
Methods
Search strategy
The relevant studies were searched through the PubMed,
Embase, Google Scholar, Wanfang, and China National
Knowledge Infrastructure (CNKI) electronic databases
updated in November 2013. There were no languages, time
period, or sample size restrictions. The search key words
were “cancer, carcinoma, tumor, neoplasms”, “LAPTM4B,
Lysosome-associated protein transmembrane-4”, and “poly-
morphism, mutation, variant”. Reference lists of retrieved
articles and reviews were checked for other eligible studies.
If the same case series was researched by more than
one study, only the one with the largest population was
included in our study. If one study investigated multiple
cancers, each cancer type was counted as a separate
comparison in the subgroup stratified by cancer type.
Inclusion and exclusion criteria
Studies included in the meta-analysis had to meet the
following inclusion criteria: (1) original case-control stud-
ies; (2) associated the LAPTM4B polymorphism with
cancer susceptibility in a Chinese population; (3) provided
sufficient information of genotype distribution in the cases
and controls; (4) did not repeat reports in the same popu-
lation. The criteria for exclusion were (1) case reports,
reviews, overlapped data, animal or mechanism studies;
(2) no genotype frequency or genotype information pro-
vided; (3) not enough information for data extraction.
Data extraction
The following data were independently extracted from all
eligible studies by two reviewers (Mo and Lu) according
to the selection criteria. Disagreements were resolvedthrough group discussion. The data collected from each
study were as follows: first author’s name, publication year,
ethnicity, cancer type, genotyping method, control source,
numbers of cases and controls, genotype distribution in
cases and controls, and Hardy–Weinberg Equilibrium
(HWE). Eligible studies were divided into hospital-based
(HB) and population-based (PB) subgroups, according
to the control source. Based on the main cancer type of
the included studies, cancer types were classified as
gastrointestinal cancer (GIC), including oesophageal, gas-
tric, colon, and rectal cancer; gynaecological cancer (GC),
including ovarian, cervical, and endometrial carcinoma;
liver cancer, lung cancer, breast cancer (BC), and others,
including gallbladder carcinoma, pancreatic cancer, naso-
pharyngeal carcinoma, and lymphoma.
Statistical analysis
All of the analysis was performed using Stata version
12.0 software (Stata Corp, College Station, TX). The
strength of association between the LAPTM4B poly-
morphism and susceptibility to multiple cancers was
assessed by odds ratio (OR) and 95% confidence interval
(95% CI) in all genetic models (allele model: *2 vs. *1;
co-dominant model: *2/2 vs. *1/1, *2/1 vs. *1/1; domin-
ant model: *2/1 + *2/2 vs. *1/1; recessive model: *2/2
vs. *2/1 + *1/1). Subgroup analyses were carried out
according to control source, cancer type, tumor grade
based on histopathologic differentiation, and tumor
stage based on TNM. The stability of the results was
assessed using sensitivity analysis by deleting each single
study involved in the meta-analysis one at a time to reflect
the influence of the individual study to the pooled ORs.
Heterogeneity was evaluated by the Chi-square-based
Q-statistic and I2 statistic. The DerSimonian–Laird ran-
dom-effects model was used to assess pooled OR when
there was a significant difference in terms of heterogeneity
(pQ < 0.1 or I
2 ≥ 50%). Otherwise, the Mantel–Haenszel
fixed-effects model was used. Potential publication bias
was estimated by funnel plots and Egger’s test. An Egger’s
test p value <0.05 was considered statistically significant.
The HWE was detected by a goodness-of-fit Chi-square
test. All p values were two-sided, and p < 0.05 for any test
was considered to be statistically significant. This article
was prepared based on the PRISMA guidelines, and the
checklist was shown in Additional file 1.
Results
Characteristics of eligible studies
Figure 1 graphically illustrates the detailed study selection
process. A total of 20 published studies associated with
the LAPTM4B gene polymorphism and susceptibility to
multiple cancers were identified for detailed evaluation
according to our search criteria. After reading the full
articles in detail, three studies were excluded because
Figure 1 Flow chart illustrates the detailed study selection process of this meta-analysis.
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http://www.biomedcentral.com/1471-2156/15/48they were case reports [12,13] and a review article [14].
Thus, 17 studies of Chinese populations, totalling 4160
cases and 4148 controls, were included in the meta-
analysis [15-31]. Table 1 lists the main characteristics
of the included studies. Among these studies, twelve
were published in English [17,18,21-29,31] and five were
published in Chinese [15,16,19,20,30]. The study of Qi
et al. was a postgraduate thesis [16]. The Zhai et al. [17]







Sun 2008 PB Liver cancer PCR
Qi 2010 HB Liver cancer PCR
Zhai 2012 PB Hepatocellular carcinoma PCR
Wang 2011 HB Primary liver cancer PCR
Deng 2005 HB Lung cancer PCR
Li 2006 PB Lung cancer PCR
Li 2012 HB Breast cancer PCR
Fan 2012 HB Breast cancer PCR
Yang 2012 PB Gallbladder carcinoma PCR
Wang 2013 HB Nasopharyngeal carcinoma PCR
Wang 2010 HB Pancreatic cancer PCR
Xu 2012 HB Ovarian cancer PCR
Meng 2011 HB Cervical carcinoma PCR
Meng 2013 HB Endometrial carcinoma PCR-RFL
Liu 2007 HB Gastric cancer PCR
Cheng 2008 HB Colon/rectal/esophageal cancer PCR
Sun 2007 HB Lymphoma PCR
HB hospital-based, PB population-based, HWE Hardy-Weinberg Equilibrium, PCR polym
length polymorphism.et al. [24] included three cancers and shared controls, so
the cancer cases were combined into a cancer group in
the overall analysis and subgroup analyses stratified by
control source and TNM stage, while each cancer was
counted as a separate comparison in the subgroup analysis
stratified by cancer type. Thirteen of the 17 eligible studies
were HB studies and the remaining four were PB studies.
The studies focused on the following cancer types: four
liver cancer [15-18]; two lung cancer [19,20]; two breastng Case/
control
HWE Case Control
*1/1 *1/2 *2/2 *1/1 *1/2 *2/2
190/175 0.587 72 110 8 99 67 9
86/78 0.799 27 51 8 36 34 7
102/135 37 52 13
303/515 0.941 107 156 40 272 205 38
162/134 0.285 54 91 21 67 59 8
131/104 0.155 70 56 5 57 36 11
208/211 0.185 90 100 18 129 76 6
732/649 0.356 326 342 64 346 262 41
91/155 0.851 34 45 12 88 57 10
134/327 0.07 74 48 12 163 145 19
58/156 0.977 24 26 8 74 67 15
282/365 0.64 122 115 45 231 108 26
317/416 0.835 127 153 37 225 163 28
P 283/378 0.072 93 135 55 200 140 38
214/350 0.484 88 107 19 199 133 18
701/350 0.484 362 293 46 199 133 18
166/350 0.484 72 71 23 199 133 18
erase chain reaction, PCR-RFLP polymerase chain reaction–restriction fragment
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http://www.biomedcentral.com/1471-2156/15/48cancer [21,22]; one cervical carcinoma [23]; one colon,
rectal, and oesophageal cancers [24]; one gallbladder car-
cinoma [25]; one gastric cancer [26]; one nasopharyngeal
carcinoma [27]; one ovarian cancer [28]; one pancreatic
cancer [29]; one lymphoma [30]; and one endometrial
carcinoma [31]. All of the patients were confirmed by
histopathologic examination. Genotype distributions in the
controls of all the studies were in agreement with HWE.
Results of meta-analysis
As shown in Table 2, obvious heterogeneity existed among
the studies; therefore, the random-effects model was used
to assess pooled OR. Overall, the LAPTM4B polymorph-
ism was significantly associated with overall susceptibility
to multiple cancers in the Chinese population in all
genetic models (*2 vs. *1, OR = 1.53, 95% CI = 1.37–
1.70, p < 0.001, Figure 2; *2/2 vs. *1/1, OR = 2.18, 95%
CI = 1.72–2.75, p < 0.001; *2/1 vs. *1/1, OR = 1.62, 95%
CI = 1.41–1.86, p < 0.001; *2/1 + *2/2 vs. *1/1, OR = 1.70,
95% CI = 1.47–1.97, p < 0.001; *2/2 vs. *2/1 + *1/1,
OR = 1.76, 95% CI = 1.50–2.05, p < 0.001).
The subgroup analysis results are provided in Table 3.
In the subgroup analysis by control source, there was a
significant association between the LAPTM4B polymorph-
ism and susceptibility to multiple cancers in both the
HB (all genetic models) and PB (allele, heterozygote,
and dominant comparison models) subgroups. When
stratified by cancer type, increased cancer susceptibility
was found in all genetic models for liver cancer and
GC. There was a significant association with risk of breast
cancer in four genetic comparisons, except the homozy-
gous model (*2/2 vs. *1/1, OR = 2.41, 95% CI = 0.97–6.01,
p = 0.059). In the lung cancer and GIC subgroups, signifi-
cant associations were only found in the heterozygote
model (lung cancer: *2/1 vs. *1/1, OR = 1.56, 95% CI =
1.11–2.29, p = 0.012; GIC: *2/1 vs. *1/1, OR = 1.33, 95%
CI = 1.03–1.73, p = 0.030). Moreover, to investigate the
relationship between LAPTM4B genotypes and cancer
clinical parameters, we analysed the distribution of his-
topathologic differentiation and classification of TNM and
found that the LAPTM4B polymorphism was associ-
ated with histopathologic differentiation (heterozygote
and dominant models). Significant association was foundTable 2 Meta-analysis of eligible studies included in the stud
Comparison models No. of studies Test of association
OR 95% CI P val
*2 vs. *1 17 1.53 1.37-1.70 <0.00
*2/2 vs. *1/1 16 2.18 1.72-2.75 <0.00
*2/1vs. *1/1 16 1.62 1.41-1.86 <0.00
*2/1 + *2/2 vs. *1/1 16 1.70 1.47-1.97 <0.00
*2/2 vs. *2/1 + *1/1 16 1.76 1.50-2.05 <0.00
OR odds ratio, 95% CI 95% confidence interval, R random-effects model.in the allele, heterozygote, and dominant comparison
models in the TNM I–II subgroup and in all genetic
models in the TNM III–IV subgroup.
Sensitivity analysis
In order to test whether the modification of the inclusion
criteria of the meta-analysis affected the pooled ORs, we
performed a sensitivity analysis by deleting each single
study involved in the meta-analysis, one at a time. The
pooled ORs were not materially altered, suggesting that
our results were statistically robust (data not shown).
Publication bias
Egger’s test and Begg’s funnel plot were conducted to
estimate the possible publication bias of the studies. The
Egger’s test results suggested no publication bias for all the
genetic models (Table 2). Figure 3 shows the shape of the
Begg’s funnel plots for the allele comparison *2 vs. *1 of
the LAPTM4B polymorphism in the overall population,
indicating no obvious publication bias in the meta-analysis.
Discussion
Meta-analysis is a valuable tool for estimating the effect
of a genetic factor on the risk of a disease when the indi-
vidual sample sizes are small [32,33]. While previous
studies have reported that LAPTM4B polymorphism is
associated with the risk of several cancers, the results
are controversial. Therefore, we carried out this meta-
analysis of 17 studies involving 8308 samples, identified
through a database search. Overall, we found a significant
association between the LAPTM4B polymorphism and
susceptibility to multiple cancers in all genetic models.
This support from our meta-analysis indicates that the
LAPTM4B polymorphism is a possible susceptibility factor
for multiple cancers in the Chinese population, especially
for liver cancer and GC.
Cancer is a multifactorial disease and its etiology is
still unclear [1]. LAPTM4B is a novel cancer-associated
gene belonging to the mammalian LAPTM family and
upregulated in a wide variety of solid tumors [11,34].
LAPTM4B has been shown to promote the transition
from G1 to S phase and cell malignant proliferation in
LAPTM4B cDNA transfected cells by upregulating they
Mode Test of heterogeneity Publication bias
ue x2 PQ Value I
2 Pbias
1 R 40.26 0.001 60.3 0.705
1 R 27.30 0.026 45.0 0.360
1 R 31.27 0.008 52.0 0.595
1 R 38.05 0.001 60.6 0.698
1 R 22.05 0.110 32.0 0.265
Figure 2 Forest plots of LAPTM4B polymorphism and overall susceptibility to multiple cancers in allele genetic model (*2 vs. *1) using
a random-effect model.
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expression of LAPTM4B may activate the integrin-α6
mediated PI3K-AKT signalling pathway and upregulate
some proto-oncogenes such as c-myc, c-jun, and c-fos,
which regulate apoptosis and cell proliferation [36]. More-
over, knockdown LAPTM4B and mutated PPRP motif in
the N-terminal region of LAPTM4B could attenuate its
role in tumorigenesis and metastasis [37]. Previous studies
have revealed that the different 19-bp sequence between
the *2 and *1 alleles might act as a cis-element, involved in
genetic transcriptional regulation. In addition, the extra
53 amino acids at the protein N-terminus produced by
LAPTM4B*2 could influence the biological activity and
function of tumor cells and then induce oncogenic sus-
ceptibility [5].
Previous studies have reported that the increased risk
for individuals carrying allele *2 were significantly asso-
ciated with a susceptibility to liver cancer [17-20], breast
cancer [23,24], cervical carcinoma [25], gallbladder car-
cinoma [27], gastric cancer [28], ovarian cancer [29],
lymphoma [32], and endometrial carcinoma [33]. However,
no statistical differences were found in nasopharyngeal
carcinoma [29] or pancreatic cancer [31]. Deng [21] found
that LAPTM4B*2 was a risk factor for lung cancer, while
Li [22] reported that LAPTM4B*2 was not closely associ-
ated with a susceptibility to lung cancer. Furthermore, the
Cheng study indicated that the LAPTM4B polymorphism
was associated with the development of colon cancer,
but not with rectal or oesophageal cancers [26]. Con-
sidering these controversial results, we performed the
present meta-analysis to establish a more conclusiveassociation between the LAPTM4B polymorphism and
cancer susceptibility.
To the best of our knowledge, this meta-analysis is the
first study to investigate the association between the
LAPTM4B polymorphism and susceptibility to multiple
cancers in a large number of Chinese populations. Our
results suggested that the LAPTM4B*2 allele was associ-
ated with a risk of susceptibility to multiple cancers, which
is consistent with the most of the original research. Signifi-
cant heterogeneity was observed in all of the genetic
model comparisons, which might be due to the control
sources and mix of cancers. Most of the studies used
hospital-based patients as controls, who were not strictly
healthy individuals and could not represent the general
population. In this meta-analysis, many cancers were
only researched once, and some polymorphisms may
play different roles in different cancers. After subgroup
analyses were conducted to consider the evidence of
heterogeneity, some heterogeneity in the control source
and cancer type subgroups was found. Therefore, we
speculated that environment components and difference
of clinicopathological characteristic might contribute to
the heterogeneity. In order to assess the influence of the
individual data set to the pooled ORs, a sensitivity analysis
was carried out by deleting each single study involved
in the meta-analysis each time. The results did not alter,
suggesting that our meta-analysis results were stable
and credible.
In further subgroup analyses, we found that the
LAPTM4B polymorphism was associated with HB or
PB study design, liver cancer, lung cancer, breast cancer,
Table 3 Stratified analysis of LAPTM4B gene polymorphism on cancer susceptibility
N *2 vs. *1 *2/2 vs. *1/1 *2/1 vs. *1/1 *2/1 + *2/2 vs. *1/1 *2/2vs. *2/1 + *1/1
OR (95% CI) p PQ OR (95% CI) p PQ OR (95% CI) p PQ OR (95% CI) p PQ OR (95% CI) p PQ
Control source
HB 13 1.53 (1.36-1.73) <0.001 0.002 2.33 (1.96-2.76) <0.001 0.234 1.58 (1.36-1.84) <0.001 0.007 1.67(1.52-1.83) <0.001 0.001 1.86(1.58-2.19) <0.001 0.612
PB 4 1.49 (1.06-2.092) 0.020 0.023 1.16 (0.35-3.80) 0.811 0.016 1.87 (1.40-2.49) <0.001 0.247 1.72(1.09-2.72) 0.019 0.073 0.88(0.30-2.54) 0.806 0.029
Cancer type
Liver cancer 4 1.66 (1.43-1.94) <0.001 0.714 2.15 (1.42-3.25) <0.001 0.312 2.03 (1.61-2.57) <0.001 0.847 2.06 (1.64-2.58) <0.001 0.963 1.52 (1.02-2.24) 0.037 0.220
Lung cancer 2 1.24 (0.63-2.41) 0.534 0.013 1.13 (0.13-9.50) 0.912 0.003 1.59 (1.11-2.29) 0.012 0.268 1.49 (0.77-2.89) 0.234 0.058 0.90 (0.14-5.90) 0.915 0.007
Breast cancer 2 1.51 (1.09-2.11) 0.014 0.058 2.41 (0.97-6.01) 0.059 0.075 1.49 (1.23-1.81) <0.001 0.187 1.55 (1.29-1.87) <0.001 0.101 1.64 (1.13-2.38) 0.009 0.116
GC 3 1.81 (1.58-2.07) <0.001 0.253 2.90 (2.16-3.90) <0.001 0.638 1.89 (1.56-2.29) <0.001 0.584 2.07 (1.73-2.48) 0.007 0.400 2.14 (1.62-2.84) <0.001 0.716
GIC 4 1.26 (0.97-1.65) 0.084 0.008 1.49 (0.77-2.88) 0.236 0.024 1.33 (1.03-1.73) 0.030 0.084 1.36 (1.00-1.84) 0.050 0.020 1.32 (0.76-2.30) 0.331 0.069
Others 4 1.39 (1.01-1.92) 0.043 0.020 2.32 (1.56-3.46) <0.001 0.257 1.26 (0.81-1.96) 0.316 0.020 1.39 (0.89-2.19) 0.150 0.011 2.10 (1.43-3.09) <0.001 0.546
Histopathologic differentiation
poor 4 1.61 (0.96-2.70) 0.069 0.006 2.34 (0.64-8.59) 0.200 0.008 2.03 (1.10-3.75) 0.024 0.050 2.07 (1.05-4.12) 0.037 0.015 1.56 (0.62-3.95) 0.346 0.060
moderate 4 1.29 (0.96-1.72) 0.091 0.341 0.98 (0.44-2.20) 0.959 0.333 1.83 (1.23-2.74) 0.003 0.527 1.67 (1.13-2.47) 0.010 0.341 0.73 (0.33-1.59) 0.425 0.523
well 4 1.48 (0.88-2.50) 0.143 0.060 2.14 (0.53-8.60) 0.284 0.045 1.60 (1.00-2.55) 0.049 0.172 1.60 (1.03-2.50) 0.037 0.121 1.35 (0.67-2.73) 0.398 0.146
TNM stage
I-II 8 1.38 (1.04-1.84) 0.028 0.006 1.89 (0.89-4.00) 0.097 0.005 1.43 (1.16-1.77) 0.001 0.415 1.49 (1.22-1.82) <0.001 0.096 1.61 (0.81-3.18) 0.175 0.008
III-IV 8 1.56 (1.31-1.87) <0.001 0.032 2.23 (1.67-2.98) <0.001 0.075 1.79 (1.40-2.28) <0.001 0.047 1.86 (1.44-2.40) <0.001 0.017 1.70 (1.29-2.23) <0.001 0.276



















Figure 3 Funnel plot to assess the publication bias of the
meta-analysis in allele genetic model (*2 vs. *1).
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http://www.biomedcentral.com/1471-2156/15/48GC, and GIC. Two studies researched the relationship
of the LAPTM4B polymorphism with lung and breast
cancers, respectively, and they may lack power of statis-
tical analysis. Thirteen studies researched the relationship
of LAPTM4B polymorphism with cancer histopathologic
differentiation, of which four provided gene frequency
data. Eight studies researched the association between
LAPTM4B polymorphism and tumor TNM stage, and
only three found that LAPTM4B polymorphism was
significantly associated with cancer histopathologic differ-
entiation and TNM stage, while the present meta-analysis
indicated that LAPTM4B polymorphism was associated
with histopathologic differentiation and TNM stage. The
small sample sizes in the individual original research stud-
ies might account for the false positive correlation. Thus,
further studies with larger sample sizes and better design
are needed.
Our meta-analysis has several advantages. First, this is
the first systematic review of the association between
LAPTM4B polymorphism and susceptibility to multiple
cancers, and it is statistically more powerful than any
single study. Second, all of the eligible studies researched
Chinese populations. The participants have the same
genetic background, which can reduce the effects of
ethnicity on pooled ORs. Third, the distributions of the
genotypes in the controls of the included studies met
HWE, which increased the statistical power of the
meta-analysis. Lastly, we analysed subgroups stratified
by control source, cancer types, histopathologic differ-
entiation, and TNM stage. Furthermore, the sensitivity
analysis and publication bias analysis indicated that our
meta-analysis results were stable and credible. However,
there were still some limitations. First, the meta-analysis
was based on unadjusted data; the controls were not
strictly matched with the cases in some of the original
research, which might have caused some bias. Second,there is notable heterogeneity among studies in the overall
analysis and in some subgroup analysis, which could lead
to some skewed results. Third, the sample size of some
of the subgroups was relatively small. In addition, only
one study investigated the association in several human
cancers. Given these limitations, the present meta-analysis
results should be considered with caution. Further studies
with larger sample sizes, more cancer types, and other
populations are needed to replicate our results.
Conclusion
This meta-analysis indicates that the LAPTM4B*2 allele is
associated with elevated susceptibility to multiple cancers.
In addition, our results indicate a significant association
between the LAPTM4B polymorphism and cancer sus-
ceptibility in the subgroups stratified by control source,
cancer type, tumor stage based on TNM, and tumor
histopathologic differentiation. All of these results indicate
that LAPTM4B may be an important biomarker for tumor
initiation and development.
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
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